1. William W. Culbertson, MD Bascom Palmer Eye Institute, Miami, FL
Laser in Situ Keratomileusis (LASIK) using the Zeiss VisuMax- MEL80 Platform for the Correction of Myopia
Victoria S. Chang, BS
Richard M. Awdeh, MD
Takeshi Ide, MD, PhD
William W. Culbertson, MD
Sonia H. Yoo, MD
Bascom Palmer Eye Institute, Miami, FL
*The first author has no financial or proprietary interest in any materials or methods described herein. WWC and SHY have received speaker's honoraria from Carl Zeiss Meditec.

2. VisuMax Femtosecond System
10 ^-15s optical pulse (ultra-short pulse duration)
 zone of collateral damage
Spherical corneal interface:  IOP elevation
No vision loss during suction
Internal fixation target
Auto centration during docking
 surgeon choice in flap parameters
Submicron tissue disruption 0.2 uJ
Repetition rate 200kHz
Precise focusing 1.0 um

3. MEL 80 Excimer Laser Fast Ablation and Eye Tracker
250 Hz repetition rate
Automatic lock on pupil center
Additional limbus tracking
Corrects for asymmetrical pupil shift
Gaussian beam – 0.7mm
Optimized beam fluence/shot distribution pattern
Additional peripheral pulses based on corneal curvature and RX

4. Purpose
To report the visual acuity outcomes, predictability, and safety of the Zeiss VisuMax-MEL80 platform for the treatment of myopia.

5. Methods
Retrospective review of initial series of 46 eyes of 26 patients treated for myopia using the Zeiss Visumax-MEL80 platform
All eyes had a treatment goal of emmetropia.
All data was analyzed using JMP (SAS, Cary, NC) and SPSS (SPSS Inc, Chicago, Illinois)
All Snellen visual acuities were converted to a logMAR scale based on a logMAR conversion table
Individual letter adjustments where accounted for as 0.02 logMAR per letter.
A Snellen acuity was rounded down one Snellen line if the logMAR score was >0.04 for that respective line.
LogMAR scores were converted back to Snellen fractions for the purposes of categorizing the results

6. Patient Characteristics
Demographics
Patient Characteristics
Characteristic
All Patients
(N=46)
Age mean (SD)
33.13 (8.97)
Female N (%)
25 (54.3)
Preoperative UCVA mean (range)
1.11 logMAR (0.21 – 1.34)
Preoperative MRSE mean (range)
-3.97 D ( )
Time to post-operative month one visit
43.8 days( 28 – 90)

7. Preoperative MRSE & UCVA
-3.97 (SD: 1.67; Range: ).
1.11 logMAR (SD: 0.29; Range: 0.21 – 1.34)

8. Post-operative Day 1 and Month 1
POD 1 UCVA
73.9% of eyes had UCVA of 20/20 or better
91.3% of eyes had UCVA of 20/25 or better
POM 1 UCVA
logMAR (SD: 0.09, Range: – 0.28)
87.0% had UCVA of 20/20 or better
97.9% of eyes had UCVA of 20/25 or better
POM 1 BCVA
(SD: 0.078; Range: -0.3 – 0.04)
100% of eyes had BCVA of 20/20
or better

9. Pre-op and Post-op UCVA

10. POM 1 MRSE 89.1% of eyes were within +/- 0.50 D of emmetropia

11. POM 1 Attempted vs. Achieved SE
r2 = 0.945

12. Conclusion
Our results show that LASIK using the VisuMax- MEL80 platform is effective, predictable, and safe in the treatment of myopia.
References
Holladay JT. Visual acuity measurements. J Cataract Refract Surg 2004; 30(2):
Shen N, Schaffer CB, Datta D, Mazur E. Surface and bulk photodisruption in turbid tissue using femtosecond laser pulses. Dept. of Physics. Harvard University.